Healthcare
Live Price
Offline$15.84
+4.14% today
1Y Change
-6.66%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SI-BONE, Inc. (SIBN) is a Healthcare stock with a market cap of $580.00M and listed on NASDAQ. The stock last traded around $15.84 and down 6.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +20.2%, EPS growth of +41.3%, a dividend yield of 0.0%. What stands out right now is revenue +20.2%, EPS +41.3%, free cash flow +60.3% with operating margin -11.1% and ROIC -10.4%. Valuation is more restrained than many high-expectation growth names at price/sales 2.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SIBN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SIBN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SIBN Max Drawdown
-45.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SIBN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$90.2M
-15.3% YoY
FY Net Income
-$56.6M
+7.6% YoY
Free Cash Flow
-$45.9M
+10.2% YoY
Revenue Growth
+20.2%
EPS Growth
+41.3%
Gross Margin
79.6%
Net Margin
-9.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 201M | 167M | 139M | 106M | 90M |
| Gross Profit | 160M | 132M | 109M | 91M | 80M |
| Operating Income | -22M | -35M | -47M | -60M | -52M |
| EBITDA | -11M | -23M | -34M | -55M | -51M |
| Net Income | -19M | -31M | -43M | -61M | -57M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42M | 35M | 33M | 21M | 63M |
| Total Assets | 239M | 230M | 230M | 158M | 191M |
| Total Liabilities | 61M | 63M | 61M | 59M | 56M |
| Shareholder Equity | 178M | 167M | 169M | 98M | 134M |
| Total Debt | 1M | 37M | 39M | 39M | 40M |
| Net Debt | -41M | 3M | 6M | 19M | -23M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
40M
+5.1% YoY
Capital Expenditures
6M
+32.8% YoY
Free Cash Flow
46M
+10.2% YoY
Key ratios
Gross Margin
79.6%
Operating Margin
-11.1%
Net Margin
-9.4%
ROE
-11.0%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.